Rare Discussions
FDA Approves Gazyva to Reduce Relapse Risk in Patients With Idiopathic Nephrotic Syndrome
10:37
Andrea Callaway, president and founder of The Nephrotic Syndrome Foundation, discusses the FDA approval of Gazyva (obinutuzumab) for idiopathic nephrotic syndrome (INS) and what the approval means for affected families. INS is a rare autoimmune kidney disease that’s commonly diagnosed in early childhood. It causes the kidneys to leak large amounts of protein into the urine, which can result in…